Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC 648265, IND 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC 373364, IND 1969) vs. Observation in Previously Untreated Patients With AML < 60 Years

Trial Profile

Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC 648265, IND 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC 373364, IND 1969) vs. Observation in Previously Untreated Patients With AML < 60 Years

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2013

At a glance

  • Drugs Valspodar (Primary) ; Cytarabine; Daunorubicin; Etoposide; Interleukin-2
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Mar 2012 Actual end date changed from Jan 2010 to Apr 2016 as reported by ClinicalTrials.gov.
    • 02 Jun 2010 Primary endpoint 'Disease free survival' has not been met.
    • 02 Jun 2010 Primary endpoint 'Overall survival' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top